$84.98
+1.5%Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Chief Financial Officer and Executive Vice President of Finance, Operations & Supply Chain
Compensation
$1,879,489
Group President of Asia Pacific
Compensation
$1,404,260
Group President of Europe, Middle East & Africa
Compensation
$1,474,629
President of Americas
Compensation
$1,196,403
President, Chief Executive Officer & Chairman of the Board
Compensation
$3,242,719
President, Chief Executive Officer & Director
Compensation
$3,242,719
Senior Vice President & Chief Communications Officer
Senior Vice President & Chief Information and Technology Officer
Senior Vice President of Investor Relations
Senior Vice President, General Counsel & Secretary
Compensation
$1,323,358
Senior Vice President, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific
Vice President, Controller & Chief Accounting Officer
During the last 12 months, insiders have sold $1.30M worth of ZBH shares, with no buying activity reported.
0
0.00
6.8K
597.94K
-598K
-$598K
0
0.00
1.0K
96.49K
-96K
-$96K
0
0.00
2.7K
280.53K
-281K
-$281K
0
0.00
3.3K
322.75K
-323K
-$323K
No buying activity
Yi Sang
Officer: Group President, Asia Pacific
$737K
Winkler Lori
Officer: Svp And Chro
$561K
Strong bearish signal with $1.30M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
ZBH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 22, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 14, 2025 | April 09, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 27, 2024 | May 10, 2024 | 2024 | |
DEF 14A DEF 14A N/A | March 30, 2023 | March 30, 2023 | ||
DEF 14A DEF 14A 2022 N/A | March 29, 2022 | May 13, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | March 31, 2021 | May 14, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 25, 2020 | May 08, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 27, 2019 | May 10, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 02, 2018 | May 15, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | March 30, 2017 | May 12, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.